non-small cell lung cancer (NSCLC)
Conditions
Interventions
Experimental group:camrelizumab combined with platinum-containing chemotherapy
Sponsors
Affiliated Cancer Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients with stage IIA-IIIA non-small cell lung that have achieved R0 resection and postoperative pathological confirmation; 2. Have not received neoadjuvant therapy before; 3. Have not received radiotherapy before; 4. Expected survival period > 3 months; 5. Aged >=18 years, no gender limit; 6. ECOG PS: 0-1 points; 7. The functions of vital organs meet the following requirements: (1) Absolute neutrophil count >= 1.5 x 10^9/L, platelets >= 100 x 10^9/L, hemoglobin >= 9g/dL; (2) Bilirubin 60 mL/min; 8. Women of childbearing age must have a negative pregnancy test (ßHCG) before starting treatment, women of childbearing age and men (who have sex with women of childbearing age) must agree to use effective contraception without interruption during treatment and for 6 months after the last therapeutic dose; 9. The patients voluntarily joined the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. EGFR gene mutation positive or ALK positive; 2. Suffering from other malignant tumors in the past or at the same time, except for the cured skin basal cell carcinoma and cervical carcinoma in situ; 3. Active tuberculosis infection. Patients with active pulmonary tuberculosis infection within 1 year before dosing, even if they have been treated, should be excluded. Patients with a history of active pulmonary tuberculosis infection more than 1 year ago are also excluded, unless it is proved that they have received standard anti-tuberculosis treatment before; 4. Those with uncontrolled or symptomatic brain metastases or with a history of uncontrollable mental illness or with severe intellectual or cognitive dysfunction; 5. Suffering from active, known or suspected autoimmune disease, patients with hypothyroidism who only receive hormone replacement therapy, and skin diseases that do not require systemic therapy (such as vitiligo, psoriasis, or alopecia) can be enrolled; 6. Congestive heart failure, uncontrollable arrhythmia, myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack within 6 months; 7. Patients who cannot comply with the trial protocol or who cannot cooperate with follow-up; 8. Have a history of psychotropic substance abuse, alcoholism or drug use; 9. Human immunodeficiency virus (HIV, HIV 1/2 antibody) positive; 10. The researchers believe that it is not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival (DFS) rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactXu Shidong
Affiliated Cancer Hospital of Harbin Medical University
Outcome results
None listed